Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted FAP theranostic study of [177Lu]Lu-FAPI in advanced lung cancer
ChiCTR2600135080Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Sep 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium-177 FAPI in bronchial carcinoma, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Incidence of adverse events. Started Sep 2025; status: recruiting.
02
Drugs
lutetium-177 FAPI
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2600135080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135080.